Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

USA - NASDAQ:PYXS - US7473241013 - Common Stock

3.36 USD
+0.01 (+0.3%)
Last: 10/17/2025, 8:00:01 PM
3.3989 USD
+0.04 (+1.16%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PYXS. PYXS was compared to 534 industry peers in the Biotechnology industry. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYXS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PYXS has reported negative net income.
In the past year PYXS has reported a negative cash flow from operations.
PYXS had negative earnings in each of the past 5 years.
PYXS had a negative operating cash flow in each of the past 5 years.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -78.14%, PYXS is doing worse than 66.73% of the companies in the same industry.
With a Return On Equity value of -109.86%, PYXS perfoms like the industry average, outperforming 42.80% of the companies in the same industry.
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

PYXS has a Gross Margin of 555.71%. This is amongst the best in the industry. PYXS outperforms 100.00% of its industry peers.
PYXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 555.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PYXS has more shares outstanding
The number of shares outstanding for PYXS has been increased compared to 5 years ago.
The debt/assets ratio for PYXS is higher compared to a year ago.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -2.53. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
PYXS's Altman-Z score of -2.53 is in line compared to the rest of the industry. PYXS outperforms 48.04% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
PYXS has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: PYXS outperforms 49.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.53
ROIC/WACCN/A
WACC9.37%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.65 indicates that PYXS has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.65, PYXS is doing good in the industry, outperforming 60.56% of the companies in the same industry.
A Quick Ratio of 5.65 indicates that PYXS has no problem at all paying its short term obligations.
PYXS has a better Quick ratio (5.65) than 60.93% of its industry peers.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.65
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

2

3. Growth

3.1 Past

PYXS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.81%.
The Revenue for PYXS has decreased by -82.53% in the past year. This is quite bad
EPS 1Y (TTM)-0.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.45%
Revenue 1Y (TTM)-82.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -0.08% on average over the next years.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 34.22% on average per year.
EPS Next Y-37.43%
EPS Next 2Y-12.29%
EPS Next 3Y-11.59%
EPS Next 5Y-0.08%
Revenue Next Year-79.63%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y34.22%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PYXS's earnings are expected to decrease with -11.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.29%
EPS Next 3Y-11.59%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (10/17/2025, 8:00:01 PM)

After market: 3.3989 +0.04 (+1.16%)

3.36

+0.01 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners33.73%
Inst Owner Change-0.14%
Ins Owners5.69%
Ins Owner Change0%
Market Cap208.39M
Analysts85.71
Price Target6.12 (82.14%)
Short Float %9.18%
Short Ratio7.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.17%
Min EPS beat(2)-16.71%
Max EPS beat(2)16.37%
EPS beat(4)2
Avg EPS beat(4)3.97%
Min EPS beat(4)-16.71%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)15.93%
EPS beat(12)7
Avg EPS beat(12)16.36%
EPS beat(16)7
Avg EPS beat(16)-119.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.39%
EPS NY rev (1m)1.79%
EPS NY rev (3m)7.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.03%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 73.9
P/FCF N/A
P/OCF N/A
P/B 2.38
P/tB 2.45
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.05
BVpS1.41
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 555.71%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.65
Altman-Z -2.53
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.45%
EPS Next Y-37.43%
EPS Next 2Y-12.29%
EPS Next 3Y-11.59%
EPS Next 5Y-0.08%
Revenue 1Y (TTM)-82.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-79.63%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y34.22%
EBIT growth 1Y-24.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.73%
OCF growth 3YN/A
OCF growth 5YN/A